π₯ Crusoe Tripled to $30 Billion in Under a Year. A Trading Firm Just Handed It a $13 Billion Bill.
Crusoe raised ~$3B at a $30B valuation, roughly tripling in 11 months, then signed a $13B AI cloud deal with trading firm Jane Street.
Crusoe raised ~$3B at a $30B valuation, roughly tripling in 11 months, then signed a $13B AI cloud deal with trading firm Jane Street.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
Broadcom sold $16.7B of custom AI chips in one quarter, up 221%, with Google, Anthropic and OpenAI on the roster. So why did the stock fall?
The former Apple and PrimeSense engineers behind Face ID and the Kinect raised a $165M Series C at a $1.6B valuation to fix robots' biggest blind spot: perception.
Nvidia is paying $12.93 billion for Hugging Face, the home of open-source AI and 18 million developers. It's the chipmaker's largest acquisition ever, and it just bought the town square where every AI builder meets.
VAST, the company behind text-to-3D platform Tripo, raised ~$446M across Series B and B+ β pushing AI 3D generation into foundation-model territory.
Spanish startup iPronics raised a $125M Series B, with Nvidia participating, to swap copper for light and rewire AI data centers in sub-milliseconds.
Miami's Felix closed a $200M Series C led by a16z and General Catalyst at a ~$1.4B valuation, moving $8B in remittances for 6M+ users through a WhatsApp chat.
The Pentagon opened GenAI.mil to 3 million personnel with ChatGPT Mil and Grok for Government at IL5 clearance. Anthropic's Claude is the one vendor left out.
Starcloud closed a $250M Series A extension at a $2.3B valuation to run Nvidia GPUs in orbit. One H100 is already up there; the FCC filing asks for 88,000 satellites.
Socure raised $156M at a $5.2B valuation and bought agentic-AI startup Fravity to fight machine-speed fraud with AI agents of its own.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.